|
Company:
|
OPGEN INC (OPGN)
|
|
Form Type:
|
DEFA14A
|
|
Filing Date:
|
4/25/2022
|
|
CIK:
|
0001293818
|
|
Address:
|
9717 KEY WEST AVENUE
SUITE 100
|
|
City, State, Zip:
|
ROCKVILLE, Maryland 20850
|
|
Telephone:
|
301-869-9683
|
|
Fiscal Year:
|
12/31
|
|
|
|
|
|
Last Trade
|
Last Trade:
$0.71
|
Change:
0.0113 (1.63%)
|
Trade Time:
May 26
|
Market Cap:
$4.31M
|
|
|
|
|
|
|
Description of Business
|
|
OpGen, Inc. (the "Company") is a precision medicine company harnessing the power
of molecular diagnostics and informatics to help combat infectious disease.
Along with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, the Company is
developing and commercializing molecular microbiology solutions helping to guide
clinicians with more rapid and actionable information about life threatening
infections to improve patient outcomes and decrease the spread of infections
caused by multidrug-resistant microorganisms, or MDROs. The Company's current
product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES
Technology Platform including ARESdb, NGS technology and AI-powered
bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic
response prediction including ARESiss, ARESid, ARESasp, and AREScloud, as well
as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.
|
|
|
|